|
 |
In July 2004 Execute began working with an international consortium of scientists and business associates to secure the IPR associated with a world-leading bioprocess that allows the high-yield, low-cost manufacturing of GMP compliant recombinant human growth factor products.
Execute have since formed a new venture, CellRx to manufacture and supply human growth factors to a global customer base out of commercial and manufacturing divisions based in the Isle of Man and South Africa. The Company’s core customers will initially be: vendors that supply and; customers that use bulk and receptor grade growth factors, derived research products and/or supplemented serum-free media in the research, development and manufacture of cell-derived protein biopharmaceuticals. |
| |
